Search hospitals > Michigan > Detroit
Detroit Receiving Hospital
Claim this profileDetroit, Michigan 48201
Conducts research for Stroke
Conducts research for Traumatic Brain Injury
Conducts research for Sepsis
Conducts research for Heart Failure
Conducts research for Head Trauma
88 reported clinical trials
5 medical researchers
Summary
Detroit Receiving Hospital is a medical facility located in Detroit, Michigan. This center is recognized for care of Stroke, Traumatic Brain Injury, Sepsis, Heart Failure, Head Trauma and other specialties. Detroit Receiving Hospital is involved with conducting 88 clinical trials across 149 conditions. There are 5 research doctors associated with this hospital, such as Anthony Lagina, MD, Wazim Mohamed, MD, Wael Saasouh, MD, and Andrew M. King, MD.Top PIs
Anthony Lagina, MDDetroit Receiving Hospital7 years of reported clinical research
Studies Traumatic Brain Injury
Studies Emergency
2 reported clinical trials
4 drugs studied
Wazim Mohamed, MDWayne State University6 years of reported clinical research
Studies Epilepsy
Studies Seizures
2 reported clinical trials
3 drugs studied
Wael Saasouh, MDNorthStar Anesthesia / Detroit Medical Center3 years of reported clinical research
Studies Coronavirus
Studies Pneumonia
2 reported clinical trials
2 drugs studied
Andrew M. King, MDDetroit Receiving Hospital5 years of reported clinical research
Studies Opiate Dependence
Studies Opioid Use Disorder
1 reported clinical trial
2 drugs studied
Clinical Trials running at Detroit Receiving Hospital
Traumatic Brain Injury
Stroke
Charcot-Marie-Tooth Disease
Sleep Apnea
Pulmonary Embolism
Motor and Sensory Neuropathy
Obstructive Sleep Apnea Syndrome
Multicenter Trial
Randomized Clinical Trial
CPAP
Hyperbaric Oxygen Therapy
for Traumatic Brain Injury
This trial aims to find the best way to use hyperbaric oxygen treatment for patients with severe brain injuries. The treatment involves breathing pure oxygen at high pressure to help heal the brain. Researchers want to determine the safest and most effective settings for this treatment. Hyperbaric oxygen therapy is an existing and approved treatment for various medical conditions, including decompression sickness, air or gas embolism, and carbon monoxide poisoning.
Recruiting1 award Phase 2
Advanced Monitoring Strategy
for Severe Traumatic Brain Injury
BOOST3 is a randomized clinical trial to determine the comparative effectiveness of two strategies for monitoring and treating patients with traumatic brain injury (TBI) in the intensive care unit (ICU). The study will determine the safety and efficacy of a strategy guided by treatment goals based on both intracranial pressure (ICP) and brain tissue oxygen (PbtO2) as compared to a strategy guided by treatment goals based on ICP monitoring alone. Both of these alternative strategies are used in standard care. It is unknown if one is more effective than the other. In both strategies the monitoring and goals help doctors adjust treatments including the kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. The results of this study will help doctors discover if one of these methods is more safe and effective.
Recruiting1 award N/A7 criteria
Hyperbaric Oxygen Therapy
for Traumatic Brain Injury
There are no therapeutic agents that have been shown to improve outcomes from severe traumatic brain injury (TBI). Critical barriers to progress in developing treatments for severe TBI are the lack of: 1) monitoring biomarkers for assessing individual patient response to treatment; 2) predictive biomarkers for identifying patients likely to benefit from a promising intervention. Currently, clinical examination remains the fundamental tool for monitoring severe TBI patients and for subject selection in clinical trials. However, these patients are typically intubated and sedated, limiting the utility of clinical examinations. Validated monitoring and predictive biomarkers will allow titration of the dose of promising therapeutics to individual subject response, as well as make clinical trials more efficient by enabling the enrollment of subjects likely to benefit. Glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL) and high sensitivity c-reactive protein (hsCRP) are promising biomarkers that may be useful as 1) monitoring biomarkers; 2) predictive biomarkers in severe TBI trials. Although the biological rationale supporting their use is strong, significant knowledge gaps remain. To address these gaps in knowledge, we propose an ancillary observational study leveraging an ongoing severe TBI clinical trial that is not funded to collect biospecimen. The Hyperbaric Oxygen in Brain Injury Treatment (HOBIT) trial, a phase II randomized control clinical trial that seeks to determine the dose of hyperbaric oxygen therapy (HBOT) that that has the highest likelihood of demonstrating efficacy in a phase III trial. The proposed study will: 1) validate the accuracy of candidate monitoring biomarkers for predicting clinical outcome; 2) determine the treatment effect of different doses of HBOT on candidate monitoring biomarkers; and 3) determine whether there is a biomarker defined subset of severe TBI that responds favorably to HBOT. This proposal will: 1) inform a go/no-go decision for a phase III trial of HBOT by providing adjunctive evidence of the effect of HBOT on key biological pathways through which HBOT is hypothesized to affect outcome; 2) provide evidence to support further study of the first monitoring biomarkers of severe TBI; 3) increase the likelihood of success of a phase III trial by identifying the sub-population of severe TBI likely to benefit from HBOT; 4) create a repository of TBI biospecimen which may be accessed by other investigators. This study is related to NCT04565119
Recruiting1 award N/A1 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Detroit Receiving Hospital?
Detroit Receiving Hospital is a medical facility located in Detroit, Michigan. This center is recognized for care of Stroke, Traumatic Brain Injury, Sepsis, Heart Failure, Head Trauma and other specialties. Detroit Receiving Hospital is involved with conducting 88 clinical trials across 149 conditions. There are 5 research doctors associated with this hospital, such as Anthony Lagina, MD, Wazim Mohamed, MD, Wael Saasouh, MD, and Andrew M. King, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.